CardioMEMS HF System
Device
Abbott Laboratories
Total Payments
$17.4M
Transactions
44,069
Doctors
10,847
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $4.7M | 13,242 | 5,021 |
| 2020 | $7.2M | 5,854 | 1,819 |
| 2019 | $1.5M | 6,221 | 2,338 |
| 2018 | $1.9M | 9,400 | 3,155 |
| 2017 | $2.1M | 9,352 | 3,116 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.2M | 2,048 | 58.8% |
| Consulting Fee | $4.6M | 3,945 | 26.3% |
| Food and Beverage | $1.7M | 35,091 | 9.8% |
| Travel and Lodging | $599,421 | 2,653 | 3.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $118,528 | 98 | 0.7% |
| Space rental or facility fees (teaching hospital only) | $79,019 | 19 | 0.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $73,479 | 84 | 0.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,125 | 2 | 0.1% |
| Education | $9,938 | 129 | 0.1% |
Payments by Type
Research
$10.2M
2,048 transactions
General
$7.2M
42,021 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Hemodynamic-GUIDEd Management of Heart Failure | Abbott Laboratories | $6.2M | 0 |
| Hemodynamic Guided Monitoring in Heart Failure (HF) Trial | Abbott Laboratories | $3.2M | 0 |
| A Phase 4 Sequential Randomized Open Label Multicenter Prospective Comparative Study to Evaluate the Treatment of Atrial Fibrillation in Preserved Cardiac Function Heart Failure (TAP-CHF trial) | Abbott Laboratories | $354,915 | 0 |
| CardioMEMS HF System Post Approval Study | Abbott Laboratories | $193,955 | 0 |
| Risk Stratification for Left Ventricular Assist Device | Abbott Laboratories | $43,220 | 0 |
| PAUSE-SCD; The Pan-Asia United States PrEvention of Sudden Cardiac Death Trial | Abbott Laboratories | $30,000 | 0 |
| Inova CardioMEMs Shared-Care Registry | Abbott Laboratories | $28,250 | 0 |
| Hemodymanic Monitoring to Prevent Adverse Events Following Cardiogenic Shock (HALOShock) Trial | Abbott Laboratories | $27,000 | 0 |
| Cardiac Resynchronization Heart Failure Follow Up Clinic | Abbott Laboratories | $17,500 | 0 |
| Cardiac Resynchronization Heart Failure Follow-Up Clinic | Abbott Laboratories | $17,500 | 0 |
| RISK STRATIFICATION FOR LEFT VENTRICULAR ASSIST DEVICE | Abbott Laboratories | $16,840 | 0 |
| TAP-CHF Trial | Abbott Laboratories | $10,935 | 0 |
| Cardiac Resynchronization Heart Failurte Follow-Up Clinic | Abbott Laboratories | $8,500 | 0 |
| Feasibility and Safety of Catheter Mapping and Ablation with Mechanical Hemodynamic Support Using the Percutaneous Heart Pump | Abbott Laboratories | $7,785 | 0 |
| INvesTigation to OptimizE Hemodynamic Management of HeartMate II Left VentricuLar Assist DEvice Patients using the CardioMEMS Pulmonary ArTery Pressure Sensor in Advanced Heart Failure (INTELLECT 2-HF) | Abbott Laboratories | $7,440 | 0 |
| Guide HF | Abbott Laboratories | $4,191 | 0 |
| Using the CardioMEMS Hemodynamic Monitor in Patients with ESRD on Hemodialysis | Abbott Laboratories | $3,195 | 0 |
| Evaluation of Acute Changes Observed with CardioMEMS During CRT Programming; A Non Significant Risk Study | Abbott Laboratories | $2,000 | 0 |
Top Doctors Receiving Payments for CardioMEMS HF System
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Albany, NY | $10.4M | 2,094 |
| , M.D | Cardiovascular Disease | La Jolla, CA | $296,080 | 475 |
| Wayne Levy | Cardiovascular Disease | Seattle, WA | $280,869 | 354 |
| , M.D | Cardiovascular Disease | Cincinnati, OH | $217,986 | 260 |
| , MD | Cardiovascular Disease | Saint Louis, MO | $182,172 | 249 |
| , M.D | Cardiovascular Disease | Columbia, SC | $155,064 | 248 |
| , M.D | Internal Medicine | Saint Marys, GA | $133,859 | 203 |
| , MD | Advanced Heart Failure and Transplant Cardiology | Austin, TX | $123,915 | 235 |
| , M.D | Specialist | Washington, DC | $122,386 | 183 |
| , M.D | Cardiovascular Disease | Boston, MA | $110,206 | 80 |
| , D.O | Internal Medicine | Lancaster, PA | $101,980 | 84 |
| , MD | Internal Medicine | Boise, ID | $91,743 | 129 |
| , MD | Internal Medicine | Charlotte, NC | $81,737 | 71 |
| , M.D., | Cardiovascular Disease | Houston, TX | $80,770 | 211 |
| , M.D | Internal Medicine | San Francisco, CA | $79,370 | 106 |
| , M.D | Internal Medicine | Houston, TX | $63,203 | 97 |
| , M.D | Specialist | Los Angeles, CA | $60,689 | 101 |
| , M.D | Cardiovascular Disease | Portland, OR | $55,662 | 108 |
| , MD | Cardiovascular Disease | Jackson, MN | $46,785 | 110 |
| , MD | Cardiovascular Disease | Boston, MA | $46,360 | 64 |
| , M.D | Cardiovascular Disease | Derry, NH | $46,038 | 188 |
| , MD | Cardiovascular Disease | Minneapolis, MN | $45,625 | 44 |
| , MD | Advanced Heart Failure and Transplant Cardiology | Seattle, WA | $45,467 | 97 |
| , MD | Internal Medicine | Manhasset, NY | $42,100 | 160 |
| , MD | Advanced Heart Failure and Transplant Cardiology | Nashville, TN | $41,470 | 55 |
Ad
Manufacturing Companies
- Abbott Laboratories $17.4M
Product Information
- Type Device
- Total Payments $17.4M
- Total Doctors 10,847
- Transactions 44,069
About CardioMEMS HF System
CardioMEMS HF System is a device associated with $17.4M in payments to 10,847 healthcare providers, recorded across 44,069 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2017 to 2021. In 2021, $4.7M was paid across 13,242 transactions to 5,021 doctors.
The most common payment nature for CardioMEMS HF System is "Unspecified" ($10.2M, 58.8% of total).
CardioMEMS HF System is associated with 18 research studies, including "Hemodynamic-GUIDEd Management of Heart Failure" ($6.2M).